PDCD1 and cancer: Cancer immunotherapy with immune checkpoint inhibitors (ICIs), particularly antibodies against PD-1 and its ligand programmed death ligand 1 (PD-L1), as well as CTLA-4, has revolutionized the therapeutic management of several solid cancers, such as lung cancer and melanoma.